Clinical Trial Update: Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn Patients [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating pre-emptive intravenous immunoglobulin (IVIG) to reduce septic episodes in pediatric burn patients with burn shock; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burn Shock

Snippet

Sponsor: Cairo University | Conditions: Burn Shock | Phase 2, Phase 3 | Status: COMPLETED